AstraZeneca Pharma

8,344.50
-26.50
(-0.32%)
Market Cap
20,861.25 Cr
EPS
64.60
PE Ratio
124.83
Dividend Yield
0.29 %
Industry
Healthcare
52 Week High
9,211.00
52 Week Low
4,800.15
PB Ratio
30.80
Debt to Equity
0.01
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,836.60
#1 4,40,661.86
37.20
#1 49,887.20
12.06
#1 9,648
13.77
62.24
6,124.50
1,62,586.23
78.35
8,184.00
0.89
1,600
#1 64.53
60.86
1,542.90
1,24,606.91
24.70
26,520.70
14.17
4,155
47.38
57.59
3,285.20
1,11,186.10
59.18
10,785.70
11.59
1,656
13.54
54.31
2,415.40
99,654.22
48.14
10,615.60
19.57
1,942
-16.38
46.37
1,171.30
97,739.76
#1 18.38
28,905.40
12.36
5,578
1.69
51.52
2,085.30
95,202.48
32.75
20,141.50
#1 19.94
1,936
38.82
54.25
892.50
89,806.38
19.65
19,831.50
13.82
3,831
29.92
53.95
1,242.00
72,135.56
19.97
29,559.20
17.55
3,169
-10.04
59.05
30,725.00
65,288.48
48.97
6,097.20
10.80
1,201
16.01
55.94

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
29.27 %
Net Income Growth
62.64 %
Cash Flow Change
-52.19 %
ROE
34.50 %
ROCE
36.57 %
EBITDA Margin (Avg.)
-11.30 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
523
571
558
583
745
845
826
820
1,029
1,330
1,652
Expenses
529
547
507
525
657
711
678
719
838
1,111
1,493
EBITDA
-6
23
51
59
88
134
148
101
191
219
159
Operating Profit %
-2 %
3 %
7 %
8 %
10 %
15 %
17 %
11 %
16 %
14 %
8 %
Depreciation
15
17
16
15
15
19
20
17
16
15
26
Interest
0
0
0
0
0
1
1
1
1
1
1
Profit Before Tax
-21
6
36
44
73
114
127
83
134
220
132
Tax
0
1
15
18
18
42
34
21
35
58
53
Net Profit
-21
5
20
26
54
72
93
62
99
162
97
EPS in ₹
-8.34
2.10
8.00
10.40
21.80
28.90
37.30
24.60
39.70
64.60
39.80

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
412
403
416
461
562
706
775
857
985
1,078
Fixed Assets
101
97
87
76
75
72
81
75
69
67
Current Assets
263
267
252
321
405
542
619
706
836
933
Capital Work in Progress
12
6
5
4
7
24
4
2
1
0
Investments
0
0
0
0
0
0
0
0
0
0
Other Assets
298
299
324
382
480
611
690
780
915
1,011
Total Liabilities
412
403
416
461
562
706
775
857
985
1,078
Current Liabilities
260
234
190
207
259
327
304
333
384
357
Non Current Liabilities
1
13
2
7
2
15
15
13
12
9
Total Equity
151
156
223
247
301
364
456
511
589
712
Reserve & Surplus
146
151
218
242
296
359
451
506
584
707
Share Capital
5
5
5
5
5
5
5
5
5
5

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-64
53
38
-1
59
-90
269
96
52
5
Investing Activities
-19
-4
0
-9
4
-171
173
5
18
22
Operating Activities
-46
57
38
9
55
87
105
101
58
28
Financing Activities
0
-1
0
0
0
-6
-9
-10
-25
-44

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.69 %
0.00 %
2.74 %
2.79 %
2.90 %
2.93 %
2.89 %
DIIs
0.83 %
0.94 %
0.96 %
1.00 %
1.02 %
1.10 %
1.12 %
1.44 %
1.42 %
1.93 %
2.43 %
2.75 %
3.78 %
5.01 %
5.10 %
5.22 %
4.65 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
19.53 %
19.72 %
19.69 %
19.44 %
19.06 %
18.62 %
18.54 %
18.56 %
18.46 %
18.12 %
17.44 %
17.09 %
16.33 %
15.00 %
14.77 %
14.62 %
15.16 %
Others
4.64 %
4.34 %
4.34 %
4.57 %
4.92 %
5.28 %
5.34 %
5.01 %
5.12 %
4.95 %
2.44 %
5.15 %
2.15 %
2.20 %
2.23 %
2.24 %
2.31 %
No of Share Holders
0
63,753
68,077
66,444
62,183
57,760
53,980
49,085
42,146
38,946
32,380
29,032
29,418
27,169
27,615
27,322
32,466

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 1 2 10 16 24 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.03 0.08 0.31 0.3 0.28 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
11 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Feb 2025 6,920.30 7,535.10
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2024 7,155.25 7,410.50
08 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
08 Aug 2024 6,610.75 7,090.80
05 Jul 2024 DIVIDEND Dividend
₹ 24.00 /share
05 Jul 2024 6,011.75 7,120.15
14 Jul 2023 DIVIDEND Dividend
₹ 16.00 /share
14 Jul 2023 3,253.00 3,767.35
08 Aug 2022 ANNUAL GENERAL MEETING Annual General Meeting
NA
08 Aug 2022 2,982.60 3,079.00
08 Jul 2022 DIVIDEND Dividend
₹ 8.00 /share
07 Jul 2022 2,635.15 2,898.90
20 Aug 2021 DIVIDEND Dividend
₹ 2.00 /share
18 Aug 2021 3,406.35 3,101.65

Announcements

Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Apr 15, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Apr 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 04, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 28, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Mar 28, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 22, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 19, 2025
Closure of Trading WindowMar 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Mar 14, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Mar 07, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Mar 06, 2025
Integrated Filing (Financial)Mar 03, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Mar 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 25, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management PersonnelFeb 25, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2025
Outcome Of The Board Meeting Held On Tuesday February 11 2025Feb 11, 2025
Press ReleaseFeb 11, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday February 11 2025Feb 11, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 11, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management PersonnelFeb 11, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Feb 10, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 10, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 21, 2025
Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Tuesday February 11 2025Jan 20, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Jan 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 09, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 07, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotDec 23, 2024
Closure of Trading WindowDec 12, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Dec 09, 2024
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Dec 04, 2024
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015Nov 26, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 26, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 26, 2024
Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 22, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 20, 2024
Launch Of Budesonide Ph. Eur 160Mcg+ Glycopyrronium Ph. Eur 7.2Mcg+Formoterol Fumarate Dihydrate Ph. Eur 5Mcg Inhalation Preparations (BreztriAerosphere)Nov 18, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 18, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 13, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Nov 13, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2024
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Additional Director (Non-Executive)Nov 13, 2024
Outcome Of The Board Meeting Held On Wednesday, November 13, 2024Nov 13, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Nov 06, 2024
Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Wednesday, November 13, 2024Oct 25, 2024
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Senior Management PersonnelOct 25, 2024

Technical Indicators

RSI(14)
Neutral
48.00
ATR(14)
Less Volatile
340.60
STOCH(9,6)
Neutral
31.21
STOCH RSI(14)
Oversold
6.24
MACD(12,26)
Bearish
-71.34
ADX(14)
Weak Trend
23.52
UO(9)
Bearish
36.20
ROC(12)
Downtrend And Accelerating
-5.96
WillR(14)
Oversold
-81.11

About AstraZeneca Pharma

AstraZeneca Pharma India Limited is a biopharmaceutical company incorporated in 1979. It manufactures, distributes, and markets pharmaceutical products, focusing on cardiovascular, renal and metabolism, oncology, and respiratory diseases. The company operates in the healthcare segment and provides clinical trial services to an overseas group company. Key products include Forxiga for heart failure and chronic kidney disease, Imfinzi for biliary tract carcinoma, Lynparza for breast cancer, and oral antidiabetic drugs like Onglyza and Kombiglyze. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is indirectly owned by AstraZeneca PLC, United Kingdom. The company has manufacturing facilities in Bangalore and has expanded its R&D presence in India.
Chairperson NameNarayan K Seshadri